Valuation: Crinetics Pharmaceuticals

Market Cap 9.01B 8.17B 7.55B 6.82B 12.84B 850B 13.3B 90.75B 35.98B 454B 33.82B 33.1B 1,441B P/E 2024
-13.8x
P/E 2025 -9.41x
Enterprise Value 8.03B 7.28B 6.73B 6.08B 11.45B 757B 11.85B 80.89B 32.07B 405B 30.15B 29.51B 1,284B EV / Sales 2024
3,310x
EV / Sales 2025 447x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.13%
3 months+0.30%
6 months+131.03%
Current year+82.49%
Current year 32.3
Extreme 32.3
85.01
1 year 32.3
Extreme 32.3
85.01
3 years 24.1
Extreme 24.1
85.01
5 years 15.23
Extreme 15.23
85.01
10 years 10.63
Extreme 10.63
85.01
Manager TitleAgeSince
President 57 31/08/2026
Corporate Officer/Principal - 31/01/2026
Corporate Secretary - 31/08/2026
Director TitleAgeSince
Director/Board Member 57 31/08/2026
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Issuer sale

Chief Financial Officer

-209,427 0.1986%
01/09/26 Issuer sale

Founder

-905,240 0.8585%
01/09/26 Issuer sale

Chairman

-232,151 0.2202%

Financials

2024 2025
Net sales 1.04M 942K 871K 786K 1.48M 97.97M 1.53M 10.46M 4.15M 52.33M 3.9M 3.82M 166M 7.7M 6.97M 6.45M 5.82M 10.97M 726M 11.35M 77.49M 30.73M 388M 28.88M 28.27M 1.23B
Net income -298M -270M -250M -226M -425M -28.14B -440M -3B -1.19B -15.03B -1.12B -1.1B -47.71B -465M -422M -390M -352M -663M -43.87B -687M -4.69B -1.86B -23.44B -1.75B -1.71B -74.39B
Net Debt -1.3B -1.18B -1.09B -985M -1.86B -123B -1.92B -13.11B -5.2B -65.6B -4.89B -4.78B -208B -979M -887M -821M -741M -1.4B -92.34B -1.44B -9.86B -3.91B -49.33B -3.68B -3.6B -157B
Projected Income Statement - Annual - Crinetics Pharmaceuticals
Logo Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Crinetics Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. CRNX Stock